90jili live casino Ruben Amorim will take charge of his first Premier League game at Old Trafford on Sunday when Manchester United host Everton. The Portuguese coach has overseen two games so far, including a 1-1 draw away at Ipswich Town and a narrow 3-2 UEFA Europa League victory at home to Norwegian side FK Bodo/Glimt. United sit 13th and 12th in the Premier League and European standings respectively. On Sunday, they welcome Merseyside club Everton to Old Trafford at an earlier time of 1:30pm. Typically, the two Sunday slots for the Premier League are the later times of 2pm and 4:30pm. READ MORE: Amorim could unleash new midfield vs Everton to give United fans what they want READ MORE: I noticed a Guardiola change which proves City are in crisis While an official reason hasn't been given for the change to the earlier kick-off times, in which Chelsea vs Aston Villa and Tottenham Hotspur vs Fulham also take place at 1:30pm, it is most likely due to the Liverpool vs Manchester City clash taking place at 4pm instead of 4:30pm. The MEN has previously reported the decision was made at the request of Merseyside Police in light of supporter trouble in previous meetings between the two teams. Therefore, the earlier games have likely been moved to avoid any crossover of TV coverage, with Chelsea's game against Villa also set to be broadcast on Sky Sports. Amorim will hope his side can gain some ground in the top four chase with a victory over Everton this weekend as they will then travel to face title chasers Arsenal midweek in the Premier League. City meanwhile are desperate to address their slump after they went six games without a win following an unbelievable draw against Feyenoord on Tuesday night. Sign up to get even more from our Man United coverage We want your views, Reds. You can become even more involved with our Man United coverage by signing up. This will unlock a whole host of things - including joining the comments and taking part in our special Q&As, where you can speak directly to our reporters about what’s happening at Old Trafford this week and beyond. Click here to get started .

Hilltop Baptist Church to host Live NativitySouth Carolina No. 1 in Top 25 women's preseason poll

SVPI Airport takes innovative measures to minimise bird strikesDog food recalled in 7 states for salmonella risk after puppy litter gets sick, FDA says

Democrat Jerry Nadler steps aside from top Judiciary role, avoiding party fightFLOWERY BRANCH, Ga. (AP) — This was not the homecoming scenario Kirk Cousins would have scripted. Cousins' return to Minnesota, his NFL home from 2018 through 2023, on Sunday comes as he is hearing speculation about his job security in Atlanta. Cousins has thrown six interceptions with no touchdowns in the Falcons' three-game losing streak. That includes four picks in last week's 17-13 loss to the Los Angeles Chargers, his most in a decade. “It’s kind of the challenge always in pro football to be able to get back up off the mat and get back going,” Cousins said after Wednesday's practice. A vote of confidence from coach Raheem Morris can't silence suggestions that it's time to give rookie first-round pick Michael Penix Jr. a chance to jump-start the Falcons' struggling offense. Morris said Sunday he didn't consider removing Cousins from the game, and he repeated his support for the veteran on Wednesday. “Got to go to Minnesota and get a big-time win and Kirk’s ready to go,” Morris said before acknowledging Cousins must bounce back from “obviously a tough game.” “You know, realistically, man he is built for this and he’s ready to go,” Morris said. The losing streak has left the Falcons (6-6) struggling to remain on top of the weak NFC South. They hold the tiebreaker advantage with Tampa Bay (6-6), but need Cousins to end his turnover streak. Cousins, 36, was expected to be the reliable leader on offense after he signed a four-year, $180 million contract. He will be in the spotlight for all the wrong reasons. He said he expects a loud reception from Minnesota's fans. “They’re great fans, great football fans,” Cousins said. “As a result I think they’ll make it as hostile as they can for us.” Cousins ranks fifth in the league with 3,052 passing yards. He has 17 touchdown passes and his 13 interceptions are only one shy of his career high. Cousins insists he feels strong in his return from last season's torn Achilles tendon. He was critical of his mental mistakes in the loss to the Chargers. He said he rushed some passes, sometimes lacking the necessary velocity on his throws and giving defensive backs the opportunity to step in front of receivers for interceptions. Atlanta offensive coordinator Zac Robinson also said Cousins' lack of velocity on his throws “just goes back to, you know, decisiveness, being decisive when you do cut it loose. Certainly those things happen with quarterbacks. There might be times where, you know, you’re not as convicted on a throw. And it shows by the way the football comes out.” Morris said he still has confidence in Cousins' arm and the mental side to his game. “He’s done a great job with us, and I have no real qualms about him bouncing back and him being able to play the game the way it needs to be done,” Morris said. “He’s still an elite processor. He has the ability to make all the throws. He’s shown that throughout the year.” Vikings defensive coordinator Brian Flores also said he expects Cousins will shake out of his slump. “I know the narrative is he had a tough game last week, but he’s played some good football," Flores said. "I think the people in this building know what Kirk can do. He’s a very, very good quarterback.” Added Flores: “He’s a bounce-back type of guy, as we all know. I’m expecting his best, the best version of Kirk, the best version of that offense. It’s going to be a major challenge for us.” Atlanta's offensive production has dipped while the veteran quarterback’s turnovers have been on the rise. The Falcons were held to under 20 points in each of their three straight losses. “Have to just believe that tough times don’t last, tough people do,” Cousins said. “You have to keep pushing.” AP Pro Football Writer Dave Campbell contributed to this report. AP NFL: https://apnews.com/hub/nfl

Drug company executives had hoped that a second Trump administration would be staffed by friendly health policy officials who would reduce regulation and help their industry boom. But some of President-elect Donald Trump’s proposed nominees are instead alarming drugmakers, according to interviews with people in the industry. For health secretary, Trump chose Robert F. Kennedy Jr., a longtime vaccine skeptic with no medical or public health training who has accused drug companies of the “mass poisoning” of Americans. Trump’s pick to lead the Centers for Disease Control and Prevention is Dr. Dave Weldon, a former Congress member from Florida who raised doubts about vaccines and pushed to move most vaccine safety research from the agency. And Trump’s choice to run the Centers for Medicare and Medicaid Services, former television host Dr. Mehmet Oz, has scant experience in managing a large bureaucracy like the one he may now oversee; the agency is in charge of health care programs that cover more than 150 million Americans. In Trump’s first term as president, pharmaceutical executives largely cheered his health policy nominees. They had ties to the moderate wing of the Republican Party and decades of conventional experience, including at major drug companies. John LaMattina, who was once the top scientist at Pfizer and is now a senior partner at PureTech Health, a firm that creates biotech startups, said of those officials, “You could disagree with them, but at least there’s a certain knowledge base, and they’ve given serious thought to these issues.” He added, “We’re now seeing some people without any sort of background, and that’s worrisome.” The implications remain unclear for Americans who rely on medications or on widespread immunity from diseases that, for now, are rare. Some in the Trump administration want to speed drug approvals, potentially seeding the market with drugs of uncertain effectiveness. Kennedy has in some forums called for more independent safety reviews of established vaccines, and at other times, he has demanded fewer constraints on unconventional and unproven treatments. But Kennedy has also tapped in to veins of outrage among consumers and lawmakers, who have long vilified drug companies for setting high prices on certain drugs and reaping billions of dollars in profits rather than putting patients first. In choosing such a vociferous critic as Kennedy, the president-elect stunned the sector, causing vaccine and biotechnology stocks to plummet temporarily. And though Kennedy most recently said that he would not take vaccines away from Americans who want them, even a modest reduction in the number of people receiving certain shots could spook investors and translate into hundreds of millions of dollars of lost revenue. The industry is also concerned that drug approvals could be delayed if Kennedy makes good on his threats to fire drug regulators, or if they quit in droves to avoid working under his leadership. “There was cautious optimism on Trump when he won, and that was very rapidly replaced with concern over RFK Jr.,” said Brian Skorney, a drug industry analyst at the investment bank Baird. Drug companies’ political action committees made millions of dollars in contributions to Democrats and Republicans this election cycle, and the industry’s lobbying groups can wield considerable influence over policy and legislation. Top pharmaceutical executives have said little publicly about Trump’s picks for health policy positions, seeking to avoid alienating the people who would regulate them. Their lobbying groups have publicly issued polite statements saying they want to work constructively with the administration. But Derek Lowe, a longtime pharmaceutical researcher and industry commentator, has criticized Kennedy on his blog, calling him “a demagogue whose positions on key public health issues like vaccination are nothing short of disastrous.” “You really can’t engage with someone like that. There is no common ground,” Lowe said in an interview. Drug industry officials have a long list of concerns about Kennedy, who did not return a request for comment for this article. They are particularly worried that he could seek to undermine childhood vaccines; one way would be for him to push to revise the government’s recommendations on immunizations. Kennedy has also called for overturning legal protections that shield vaccine makers from litigation when people are seriously harmed by vaccines — a change that would upend an established compensation program and could expose the industry to costly lawsuits. The stakes appear to be highest for companies that make vaccines. About a fifth of Merck’s revenue comes from two types of vaccines that Kennedy has targeted: a vaccine against the human papillomavirus that has averted thousands of cancer cases, and the shots that children receive to protect them against measles, mumps and rubella. (Merck declined to comment.) Vaccine sales represent about 3% of the industry’s overall prescription drug revenues, according to IQVIA, an industry data provider. With some exceptions, vaccines tend to generate relatively low returns compared with profits from more expensive products used for diseases like cancer and arthritis. Drug manufacturers also fear the effect Kennedy could have at the Food and Drug Administration. They often complain that the agency can be too onerous, but their business model is reliant on a well-staffed FDA that can weed out would-be competitors that haven’t met its standards for safety and effectiveness. Kennedy regularly lambastes the FDA as “corrupt” and too close to the drug industry. He has denounced the fees the agency receives from makers of medical devices and drugs, which make up about half of its $7.2 billion annual budget. It’s unclear how Kennedy’s views will mesh with those of Jim O’Neill, a Silicon Valley investor and former government official who would serve as his deputy if he is confirmed. O’Neill, a former top aide to billionaire Peter Thiel, has called for approving drugs once they’ve been shown to be safe but before they have been shown to be effective. That idea goes well beyond the deregulation favored by most pharmaceutical executives. Karoline Leavitt, a spokesperson for Trump’s transition who will be his press secretary, described the president-elect’s choices for administration posts as “highly qualified” and reflective of “his priority to put America First.” Although lawmakers in both parties frequently criticize the drug industry for charging high prices, Kennedy paints pharmaceutical companies in a much harsher light. In an interview last year, Kennedy called vaccine makers “the most corrupt companies in the world” and “serial felons.” He has advanced falsehoods about the science underlying some of the industry’s most influential products, suggesting that vaccines cause autism and that HIV may not be the true cause of AIDS. He has embraced an increasingly popular notion that healthy food and lifestyle changes — not pharmaceutical products — will heal sick people. Referring to drug companies, he wrote on the social platform X this year, “The sicker we get the richer and more powerful they become.” “His view of our world seems to be that everything is a conspiracy,” said Brad Loncar, a former biotech investor who now runs BiotechTV, an industry media company. “If you really know our industry, it’s made up of well-intentioned, smart people, and it’s one of the most innovative sectors of our entire economy.” Pharmaceutical officials were relieved by Trump’s pick to lead the FDA, Dr. Martin Makary, who has a contrarian bent but has been aligned with scientific consensus on vaccine safety and is not seen as a threat to unwind the status quo. Drug companies hope to have an ally in Vivek Ramaswamy, who made his fortune as a biotechnology executive and has been named to lead a government efficiency effort alongside Elon Musk. Ramaswamy has been critical of what he describes as regulatory red tape that slows new drug approvals. And O’Neill, the president-elect’s choice for deputy health secretary, has close ties to some biotechnology and medical technology companies, though he is less well-connected to major industry players. Bracing for the potential of public attacks and new proposals that could hurt their bottom lines, drug companies are said to be reaching out to contacts close to Trump in hopes of influencing the incoming administration. Some are also considering new ways to defend their businesses from government initiatives they consider detrimental. “There’s no playbook for dealing with these disruptive figures like Kennedy,” said Sam Geduldig, managing partner of the right-leaning lobbying firm CGCN Group. Other lobbyists said they are instructing pharmaceutical clients not to hit the panic button yet. Once Congress returns after the Thanksgiving break, Kennedy is expected to make the rounds on Capitol Hill. He could face trouble winning the support he needs from Senate Republicans to be confirmed because of his record on vaccines, his past support for abortion rights and his ideas about overhauling the food system. Drug industry officials have long regarded Trump as a wild card, just as likely to be a boon as a foe. In 2020, the Trump administration’s Operation Warp Speed worked closely with drugmakers and poured billions of dollars into producing highly effective COVID shots in record time, saving countless lives. Trump’s pandemic-era health secretary, Alex Azar, spoke with admiration that year about “our partners in the private sector.” But this year, Trump spoke little about Operation Warp Speed. With some exceptions, the drug industry has been in something of a slump since the heights of the pandemic, when it enjoyed a boost in its public image, and investors eager to get in on huge gains poured money into drug stocks. But trust in vaccines and public health institutions has eroded at the same time as the bubble in the biotech markets has deflated. Among major COVID vaccine makers, Moderna’s stock price is down tenfold, and Pfizer’s stock price has fallen by half, from their high-water marks in 2021. An index of smaller biotechnology stocks is down by close to half. Drug company officials still see opportunities to benefit from Trump’s win. The industry is looking forward to Trump replacing Lina Khan, the chair of the Federal Trade Commission, as he is expected to do. She has been aggressive in taking on big business, including pharma. The industry is also hopeful that Trump could help reverse its worst policy defeat in recent memory. Under the 2022 Inflation Reduction Act, President Joe Biden’s signature policy achievement, Democratic lawmakers empowered Medicare to directly negotiate the prices of certain prescription drugs — cutting into manufacturers’ profits and raising the specter of similar price cuts in the commercial market. Republicans in Congress have said that they want to repeal the negotiation program. This article originally appeared in The New York Times . © 2024 The New York Times CompanyActivists Get Prison Time for Dumping Powder on Constitution CaseThe University of Washington announced Friday that the women's basketball program will retire Kelsey Plum's No. 10 in January -- making her the first player in program history to have her number retired. Plum, who currently plays for the Las Vegas Aces in the WNBA, will see her number hung from the rafters inside Alaska Airlines Arena at Hec Edmundson Pavilion on Jan. 18, during a game against Purdue. "I'm forever proud to be a Husky and UW is a special place that fundamentally shaped me both as a basketball player and as a person," Plum said in a statement. "It means the world to me to receive this honor and to celebrate it with my family, friends and alumni." Plum played for the Huskies from 2013-17 and finished her career as the all-time leading scorer in women's basketball history (Caitlin Clark of Iowa broke the record earlier this year). She also set the women's single-season scoring record (also broke by Clark in 2024). Her 912 career free throws still stand as the women's record. Plum was selected first overall by the San Antonio Stars in the 2017 WNBA Draft. The club moved to Las Vegas the following season and she has remained with the team since. In seven seasons (she missed the 2020 campaign due to an Achilles injury), the 30-year-old Plum has averaged 14.3 points and 4.0 assists over 235 career games (193 starts). She was named the league's Sixth Woman in 2021, made the All-WNBA first team the following season and has been an All-Star in each of the past three seasons. Plum and the Aces won the WNBA championship in 2022 and '23. They lost to the New York Liberty in the semifinals last month. --Field Level Media

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceLPL Financial managing director sells $101,241 in stockNone

DAMASCUS, Syria — Syria's prime minister said Monday that most cabinet ministers were back at work after rebels overthrew President Bashar Assad, but some state workers failed to return to their jobs, and a United Nations official said the country's public sector had come "to a complete and abrupt halt." Meanwhile, streams of refugees crossed back into Syria from neighboring countries, hoping for a more peaceful future and looking for relatives who disappeared during Assad's brutal rule. The rebel alliance now in control of much of the country is led by a former senior al-Qaida militant who severed ties with the extremist group years ago and promises representative government and religious tolerance. The rebel command said Monday they would not tell women how to dress. Syrian citizens stand on a government forces tank that was left on a street Monday as they celebrate in Damascus, Syria. "It is strictly forbidden to interfere with women's dress or impose any request related to their clothing or appearance, including requests for modesty," the command said on social media. Nearly two days after rebels entered the capital, some key government services shut down after state workers ignored calls to go back to their jobs, the U.N. official said, causing issues at airports and borders and slowing the flow of humanitarian aid. Rebel leader Ahmad al-Sharaa, who was long known by his nom de guerre Abu Mohammed al-Golani, also met for the first time with Prime Minister Mohammad Ghazi Jalali, who stayed in Syria when Assad fled. Israel said it carried out airstrikes on suspected chemical weapons sites and long-range rockets to keep them from falling into the hands of extremists. Israel also seized a buffer zone inside Syria after Syrian troops withdrew. Syrians wait to cross into Syria from Turkey on Monday at the Oncupinar border gate near the town of Kilis, southern Turkey. In northern Syria, Turkey said allied opposition forces seized the town of Manbij from Kurdish-led forces backed by the United States, a reminder that even after Assad's departure, the country remains split among armed groups that have fought in the past. The Kremlin said Russia granted political asylum to Assad, a decision made by President Vladimir Putin. Kremlin spokesperson Dmitry Peskov declined to comment on Assad's specific whereabouts and said Putin did not plan to meet with him. Damascus was quiet Monday, with life slowly returning to normal, though most shops and public institutions were closed. In public squares, some people still celebrated. Civilian traffic resumed, but there was no public transport. Long lines formed in front of bakeries and other food stores. There was little sign of any security presence, though in some areas small groups of armed men were stationed in the streets. Syrian citizens celebrate Monday during the second day of the takeover of the city by the insurgents in Damascus, Syria. Across swathes of Syria, families are now waiting outside prisons, security offices and courts, hoping for news of loved ones who were imprisoned or who disappeared. Just north of Damascus in the feared Saydnaya military prison, women detainees, some with their children, screamed as rebels broke locks off their cell doors. Amnesty International and other groups say dozens of people were secretly executed every week in Saydnaya, and they estimate that up to 13,000 Syrians were killed between 2011 and 2016. "Don't be afraid," one rebel said as he ushered women from packed cells. "Bashar Assad has fallen!" In southern Turkey, Mustafa Sultan was among hundreds of Syrian refugees waiting at border crossings to head home. He was searching for his older brother, who was imprisoned under Assad. "I haven't seen him for 13 years," he said. "I am going to go see whether he's alive." Jalali, the prime minister, sought to project normalcy since Assad fled. "We are working so that the transitional period is quick and smooth," he told Sky News Arabia TV on Monday, saying the security situation already improved from the day before. Israeli soldiers sit on top of a tank Monday along the so-called Alpha Line that separates the Israeli-annexed Golan Heights from Syria, in the town of Majdal Shams. At the court of Justice in Damascus, which was stormed by the rebels to free detainees, Judge Khitam Haddad, an aide to the justice minister in the outgoing government, said Sunday that judges were ready to resume work quickly. "We want to give everyone their rights," Haddad said outside the courthouse. "We want to build a new Syria and to keep the work, but with new methods." But a U.N. official said some government services were paralyzed as worried state employees stayed home. The public sector "has just come to a complete and abrupt halt," said U.N. Resident and Humanitarian Coordinator for Syria Adam Abdelmoula, noting, for example, that an aid flight carrying urgently needed medical supplies was put on hold after aviation employees abandoned their jobs. "This is a country that has had one government for 53 years and then suddenly all of those who have been demonized by the public media are now in charge in the nation's capital," Abdelmoula told The Associated Press. "I think it will take a couple of days and a lot of assurance on the part of the armed groups for these people to return to work again." People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) People gather to react following the fall of Syrian president Bashar Assad’s government, in Trafalgar Square, in London, Sunday, Dec. 8, 2024. (AP Photo/Alberto Pezzali) People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) People gather to react following the fall of Syrian president Bashar Assad’s government, in Trafalgar Square, in London, Sunday, Dec. 8, 2024. (AP Photo/Alberto Pezzali) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) Members of the Syrian community in Finland wave a Syrian flag and celebrate in Helsinki, Finland, Dec. 8, 2024. (Roni Rekomaa/Lehtikuva via AP) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) Syrians wave opposition flags and give out sweets during a spontaneous rally in Wuppertal, Germany, Sunday, Dec. 8, 2024, following the fall of Syrian president Bashar Assad’s government. (Christoph Reichwein/dpa/dpa via AP) Syrians celebrate the fall of the Assad regime in Syria at a demonstration in Stockholm, Sweden, Sunday, Dec. 8, 2024. (Jonas Ekstroemer/TT News Agency via AP) A Syrian man waves a flag during a spontaneous demonstration celebrating the fall of the Assad regime, in Nicosia, Cyprus, Sunday, Dec. 8, 2024. (AP Photo/Petros Karadjias) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) Syrians wave Syrian opposition flags at a rally in Wuppertal, Germany, Sunday, Dec. 8, 2024, following the fall of Syrian president Bashar Assad’s government. (Christoph Reichwein/dpa/dpa via AP) Syrians living in France gather on Republique square after the Syrian government fell early today in a stunning end to the 50-year rule of the Assad family, Sunday, Dec. 8, 2024 in Paris. (AP Photo/Aurelien Morissard) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) People gather to celebrate the Syrian government's fall, in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) Syrians living in France hug during a rally on Republique square after the Syrian government fell early today in a stunning end to the 50-year rule of the Assad family, Sunday, Dec. 8, 2024 in Paris. (AP Photo/Aurelien Morissard) People gather to react following the fall of Syrian president Bashar Assad’s government, in Trafalgar Square, in London, Sunday, Dec. 8, 2024. (AP Photo/Alberto Pezzali) People gather to celebrate the Syrian government fall at Faith mosque in Istanbul, Turkey, Sunday, Dec. 8, 2024. (AP Photo/Emrah Gurel) People attend a rally celebrating the fall of Syrian President Bashar Assad's government, at central Syntagma square, in Athens, Greece, Sunday, Dec. 8, 2024. (AP Photo/Yorgos Karahalis) A Syrian man waves a flag during a spontaneous demonstration celebrating the fall of the Assad regime in Nicosia, Cyprus, Sunday, Dec. 8, 2024. (AP Photo/Petros Karadjias) People wave Syrian opposition flags at City Hall Square in Copenhagen, Denmark, Sunday, Dec. 8, 2024. (Emil Nicolai Helms/Ritzau Scanpix via AP) Get local news delivered to your inbox!